Sunday, February 24, 2019 5:23:20 PM
Bored Barrister
Yeah. Not because of no news but primarily because of the completely unjustified and abjectly stupid huge salary increases reflecting greed, arrogance, and a complete absence of managerial competence. We went from a frail penniless outfit with a promising HIV drug to a frail penniless outfit that's going to heal the world. We're selling stock at 30-35* cents a copy to keep the lights on and NP gives himself a raise from $400K to $600K. Why? A sports star said it first, he needs to put food on the table.
NP doesn't exude confidence. If he really believed his snake oil pitch, he would cut everyone's salary 30%-50%
and distribute some stock options to compensate. That's what competent believers do.
The drug seems very promising and the potential gain dwarfs the risk so I reinvested but I can't get my mind around these raises/salaries. On the other hand, why would such a promising drug that might cure/control HIV and most cancers and who knows what else be languishing at half a buck with virtually all board members sitting in a current loss position?
Probably another reason I returned was personal - I tried to buy Medarex at 7 and watched it move to 100 the first year and then onto 200 the second year.
* Sales at 50 cents less roughly 15% to friend Paulson less about 10 cents avg value of 5 yr 75 cent
warrants
Yeah. Not because of no news but primarily because of the completely unjustified and abjectly stupid huge salary increases reflecting greed, arrogance, and a complete absence of managerial competence. We went from a frail penniless outfit with a promising HIV drug to a frail penniless outfit that's going to heal the world. We're selling stock at 30-35* cents a copy to keep the lights on and NP gives himself a raise from $400K to $600K. Why? A sports star said it first, he needs to put food on the table.
NP doesn't exude confidence. If he really believed his snake oil pitch, he would cut everyone's salary 30%-50%
and distribute some stock options to compensate. That's what competent believers do.
The drug seems very promising and the potential gain dwarfs the risk so I reinvested but I can't get my mind around these raises/salaries. On the other hand, why would such a promising drug that might cure/control HIV and most cancers and who knows what else be languishing at half a buck with virtually all board members sitting in a current loss position?
Probably another reason I returned was personal - I tried to buy Medarex at 7 and watched it move to 100 the first year and then onto 200 the second year.
* Sales at 50 cents less roughly 15% to friend Paulson less about 10 cents avg value of 5 yr 75 cent
warrants
Recent CYDY News
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
